Marijuana may be reclassified as a schedule III drug, leading to a potential boost for cannabis ETFs. The Trump administration’s possible move could reduce taxes for the industry and open up banking activities. This change could significantly impact the financial implications for companies involved in the cannabis industry.

US cannabis ETFs primarily use swaps rather than holding marijuana stocks directly. The largest ETF in this category is the AdvisorShares Pure US Cannabis ETF (MSOS), followed by Amplify’s Alternative Harvest ETF (MJ). MSOS has seen significant growth in recent days, although it remains below its peak value from 2021.

The rescheduling of marijuana could lead to more US listings and potential growth for cannabis ETFs like MSOS. This change may also encourage more states to legalize marijuana, creating acquisition opportunities for consumer application companies. The shift to a schedule III classification could make small cannabis companies more valuable as potential acquisition targets.

The volatility in the cannabis market due to political uncertainty may lead to rapid price changes. While the news of potential rescheduling is driving prices up, they could just as easily drop. The reclassification may also prompt more states to legalize marijuana, further boosting the value of small cannabis companies. This shift could make them attractive acquisition targets for consumer application companies.

Read more at Yahoo Finance: Cannabis ETFs Stay High on Drug Rescheduling News